Menu
Back to User profile » Dr Heleen DeCory
Papers published by Dr Heleen DeCory:
Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
Blondeau JM, Proskin HM, Sanfilippo CM, DeCory HH
Clinical Ophthalmology 2021, 15:4419-4430
Published Date: 10 November 2021
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
Fong R, Cavet ME, DeCory HH, Vittitow JL
Clinical Ophthalmology 2019, 13:1427-1438
Published Date: 1 August 2019
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
Bucci FA Jr, Evans RE, Amico LM, Morris TW, Fluet AT, Sanfilippo CM, DeCory HH, Comstock TL
Clinical Ophthalmology 2015, 9:843-852
Published Date: 13 May 2015
Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
Comstock TL, Morris TW, Gearinger LS, DeCory HH
Clinical Optometry 2014, 6:25-35
Published Date: 1 April 2014
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
Coffey MJ, DeCory HH, Lane SS
Clinical Ophthalmology 2013, 7:299-312
Published Date: 13 February 2013
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
Silverstein BE, Morris TW, Gearinger LS, DeCory HH, Comstock TL
Clinical Ophthalmology 2012, 6:1987-1996
Published Date: 30 November 2012
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
Morris TW, Gearinger LS, Usner DW, Paterno MR, DeCory HH, Comstock TL, Haas W
Clinical Ophthalmology 2011, 5:1359-1367
Published Date: 21 September 2011
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW
Clinical Ophthalmology 2011, 5:1369-1379
Published Date: 21 September 2011